Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health

 Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health

Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health

Shots:

  • Palette to receive global development rights for Nestle’s Deflux, Solesta and Barrigel and will focus on its commercialization. Nestle will continue to develop the license products for Palette
  • The licensed products are developed by using Nestle’s NASHA technology, used for injecting and creating firm gel texture. Additionally, Pharmanest AB will be renamed as Palette Life Sciences AB in Sweden and the US
  • Deflux IV & Solesta are novel FDA approved treatments for vesicoureteral reflux (VUR) & fecal incontinence respectively. Barrigel IV is EU approved treatment for protection of the rectal wall when treating prostate cancer with radiation

Click here to read full press release/ article | Ref: PRNewsWire | Image: Nestle Skin Health

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post